Comparative Pharmacology
Head-to-head clinical analysis: NORTREL 1 35 21 versus SIMPESSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORTREL 1 35 21 versus SIMPESSE.
NORTREL 1/35-21 vs SIMPESSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
Oral: 10 mg once daily, taken at least 1 hour before a meal.
None Documented
None Documented
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive